Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

• Gunter von Minckwitz, Holger Eidtmann, +20 authors Michael Untch
• The New England journal of medicine
• 2012

BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal growth factor receptor 2 (HER2)-negative… (More)

Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy

• Andrea Rieber, H.-J. Brambs, Andreas Gabelmann, Volker Heilmann, Rolf Kreienberg, Thorsten Kuehn
• European Radiology
• 2001

The objective of the present study was to monitor response to preoperative chemotherapy with breast MRI in patients with large breast cancer. Fifty-eight women in whom core biopsy had confirmed the… (More)

Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors

• Thorsten Kuehn, Wolfgang Klauss, +6 authors Rolf Kreienberg
• Breast Cancer Research and Treatment
• 2000

Objective. This study describes in detail the surgery-related symptoms following axillary lymph node dissection in breast cancer patients and considers both their significance for long term quality… (More)

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

• Michael Untch, Sibylle Loibl, +16 authors Gunter von Minckwitz
• The Lancet. Oncology
• 2012

BACKGROUND We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy. METHODS In the GeparQuinto randomised phase 3… (More)

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.

• Kerstin Hermelink, Michael Untch, +4 authors Karin Münzel
• Cancer
• 2007

BACKGROUND It is believed widely that chemotherapy-induced cognitive impairment occurs in a subgroup of patients with breast cancer. However, recent reports have provided no evidence that… (More)

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.

• Holger Schirrmeister, Albrecht Guhlmann, +11 authors Sven N. Reske
• Journal of clinical oncology : official journal…
• 1999

PURPOSE Previous studies have shown that bone metastases are revealed by magnetic resonance imaging (MRI) or bone marrow scintigraphy several months before they are visible by conventional bone… (More)

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

• Angela Reles, Wen H. Wen, +11 authors Michael F Press
• Clinical cancer research : an official journal of…
• 2001

PURPOSE The p53 tumor suppressor gene plays a central role in cell cycle regulation and induction of apoptosis. We analyzed p53 alterations and their impact on response to chemotherapy and clinical… (More)

Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years.

• Shan Wang-gohrke, Heiko Becher, Rolf Kreienberg, I B Runnebaum, Jenny Chang-Claude
• Pharmacogenetics
• 2002

We used a large population-based case-control study to determine whether three known p53 polymorphisms, intron 3 16 bp duplication, codon 72(Arg/Pro) and intron 6 MspI restriction fragment length… (More)

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

• I B Runnebaum, Shan Wang-gohrke, +19 authors Steven A Narod
• Pharmacogenetics
• 2001

Oral contraceptives have been shown to be protective against hereditary ovarian cancer. The variant progesterone receptor allele named PROGINS is characterized by an Alu insertion into intron G and… (More)

Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon…

• Ulrike Gabriella Wagner, Siegmund Köhler, +10 authors Diethelm Wallwiener
• Clinical cancer research : an official journal of…
• 2001

The aim of the present study was to assess whether the induction of specific immune responses by vaccination with the murine monoclonal anti-idiotypic antibody ACA125, which imitates the… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›